Summary
5-Hydroxytryptamine (5-HT; serotonin) has long been implicated in the aetiology of migraine but the evidence remains circumstantial and certainly not definitive. Numerous papers have reviewed the background which is briefly outlined here. Although the continued belief in the primary involvement of 5-HT in the genesis of a migraine attack has recently been questioned, many antimigraine drugs undeniably interact potently with 5-HT receptors. It can be argued, however, that their modest clinical benefit results from their pharmacological effects, be they mediated through 5-HT receptors or otherwise, independently of any pathophysiological involvement of endogenous 5-HT. Nevertheless, there seems convincing evidence that central release of 5-HT by various drug mechanisms causes migraine-like headache in migraineurs. It remains to be seen whether these drugs mimic the pathological event initiating the spontaneous migraine attack. Regardless of these considerations, the focus of research on 5-HT and migraine has proved to be enormously profitable over several decades, culminating recently in the identification of a novel, potentially important, antimigraine drug for the treatment of the acute attack. This drug, sumatriptan, is a selective cranial vasoconstrictor which mediates this effect by specifically activating a particular 5-HT1 receptor subtype. Undoubtedly a precise understanding of its clinical mechanism of action, which is currently being studied by a number of groups, will lead to a better understanding of the pathogenesis of migraine. Perhaps this in turn will help in finally determining whether migraine is a vascular disease and whether or not a disturbance of 5-HT is just epiphenomenal or is truly the primary initiating pathological event.
Similar content being viewed by others
References
Angus JA, Van Nueten JM (1989) Pathophysiology of 5-hydroxytryptamine: an overview. In: Mylecharane EJ, Angus JA, de la Lande IS, Humphrey PPA (eds) Serotonin actions, receptors, pathophysiology. Macmillan Press, Basingstoke, pp 274–279
Anthony M, Hinterberger H, Lance JW (1967) Plasma serotonin in migraine and stress. Arch Neurol 16:544–552
Anthony M, Hinterberger H, Lance JW (1967) The possible relationship of serotonin to the migraine syndrome. Res Clin Study Headache 2:29–59
Badia A, Maron A, Cuffi L, Vila E (1988) Effect of ergotamine on cardiovascular catecholamine receptors in the pithed rat. Gen Pharmacol 19:475–481
Bagdy G, Szemeredi K, Zukowska-Grojec Z, Hill J, Murphy DL (1987)m-Chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats. Life Sci 41:775–782
Blau JN, Dexter SL (1981) The site of pain origin during migraine attacks. Cephalalgia 1:143–147
Blau JN, Solomon F (1985) Migraine and intracranial swelling: an experiment of nature. Lancet II:718
Bouchard JM, Delaunay J, Delisle JP, Grasset N, Mermberg PF, Molczadzki M, Pagot R, Richou H, Robert G, Ropert R, Schuller E, Verdeau-Pailles J, Zarifian E, Hopfner-Petersen HE (1987) Citalopram versus maprotiline: a controlled, clinical, multicentre trial in depressed patients. Acta Psychiatr Scand 76:583–592
Brazil P, Friedman AP (1956) Craniovascular studies in headache: a report and analysis of pulse volume trainings. Neurology 6:96–102
Brewerton TD, Murphy DL, Mueller EA, Jimerson DC (1988) Induction of migraine-like headaches by the serotonin agonistm-chlorophenylpiperazine. Clin Pharmacol Ther 43:605–609
Buzzi MG, Moskowitz MA (1990) The anti-migraine drug sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206
Carroll JD, Hilton BP (1974) The effects of reserpine injection on methysergide treated control and migrainous subjects. Headache 14:149–156
Cohen ML, Fuller RW (1983) Antagonism of vascular serotonin receptors bym-chlorophenylpiperazine andm-trifluoromethylphenylpiperazine. Life Sci 32:711–718
Curran DA, Hinterberger H, Lance JW (1965) Total plasma serotonin, 5-hydroxyindoleacetic acid andp-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 88:997–1007
Curran DA, Lance JW (1964) Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry 27:463–469
Curran HV, Lader M (1986) The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. Eur J Clin Pharmacol 29:601–607
Curzon G, Theaker P, Phillips B (1966) Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine. J Neurol Neurosurg Psychiatry 29:85–90
Del Bene E, Anselmi B, Del Bianco PL, Fanciullacci M, Galli P, Salmon S, Sicuteri F (1977) Fenfluramine headache: a biochemical and monoamine receptorial human study. In: Sicuteri F (ed) Headache: new vistas. Biomedical Press, Florence, pp 101–109
Drummond PD, Lance JW (1983) Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol 13:32–37
Dvilansky A, Rishpon S, Nathan I, Zolotow Z, Korczyn AD (1976) Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks. Pain 2:315–318
Edmeads J (1991) What is migraine? Controversy and stalemate in migraine pathophysiology. J Neurol 238 (suppl 1):S2-S5
Feniuk W, Humphrey PPA, Perren MJ: GR43175 does not share the complex pharmacology of the ergots. Cephalalgia 9 (suppl 9):35–39
Feniuk W, Humphrey PPA, Perren MJ, Connor HF, Whalley ET (1991): Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol 238 (suppl 1):S57-S61
Ferrari MD (1991) 5-HT3 receptor antagonists and migraine therapy. J Neurol 238 (suppl 1):S53-S56
Ferrari MD, Fröhlich M, Odink J, Tapparelli C, Portielje JEA, Bruyn GW (1987) Methionine-enkephalin and serotonin in migraine and tension headache. In: Rose FC (ed) Advances in headache research. John Libbey, London, pp 227–234
Ferrari MD, Odink J (1989) Urinary excretion of biogenic amines camines in migraine and tension headache. In: Rose FC (ed) New advances in headache research. Smith-Gordon, London, pp 85–88
Ferrari MD, Odink J, Tapparelli C, Van Kempen GMJ, Pennings EJM, Bruyn GW (1989) Serotonin metabolism in migraine. Neurology 39:1239–1242
Fozard JR (1975) The animal pharmacology of drugs used in the treatment of migraine. J Pharm Pharmacol 27:297–321
Fozard JR (1982) Serotonin, migraine and platelets. Prog Pharmacol 4:136–146
Fozard JR (1990) 5-HT in migraine: evidence from 5-HT receptor antagonists for a neuronal aetiology. In: Sandler M, Collins G (eds) Migraine — a spectrum of ideas. Oxford University Press, Oxford, pp 128–146
Fozard JR, Gray JA (1989) 5-HT1C receptor activation: a key step in the initiation of migraine? Trends in Pharmacol Sci 10:307–309
Friberg (1991) Cerebral blood flow changes in migraine: methods, observations and hypotheses. J Neurol 238 (suppl 1):S12-S17
Genefke IK, Dalsgaard-Nielsen T, Bryndum B, Fog-Moller F, Jensen JAP (1975) Concentration of serotonin in blood platelets: effect of reserpine in migraineurs. Headache 15:136–138
Goltman AM (1935) Mechanism of migraine. J Allergy 7:351–355
Gomersall JD, Stuart A (1973) Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 36:684–690
Graham JR, Wolff HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 39:737–763
Hachinski V, Norris JW, Edmeads J, Cooper PW (1978) Ergotamine and cerebral blood flow. Stroke 9:594–596
Hamel E, Robert J-P, Young AR, MacKenzie ET (1989) Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery. J Pharmacol Exp Ther 249:879–889
Hanko J, Hardebo JE, Kahstrom J, Owman C, Sundler F (1985) Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibers and dilates pial and peripheral arteries. Neurosci Lett 57:91–95
Heyck H (1969) Pathogenesis of migraine. Res Clin Study Headache 2:128
Horton BT, Peters GA, Blumenthal LS (1945) New product in the treatment of migraine; preliminary report. Proc Staff Meet Mayo Clin 20:241–248
Hoyer D (1988) Molecular pharmacology and biology of 5-HT1C receptors. Trends in Pharmacol Sci 9:89
Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (−)-[125H]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol 118:13–23
Humphrey PPA, Feniuk W, Watts AD (1982) Ketanserin — a novel hypertensive drug? J Pharm Pharmacol 34:541
Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW (1989) The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 9(suppl 9):23–33
Humphrey PPA, Feniuk W, Perren MJ, Oxford AW, Brittain AT (1989) Sumatriptan succinate. Drugs of the Future 14:35–39
Humphrey PPA, Apperley E, Feniuk W, Perren MJ (1990) A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine. Kluwer, Dordrecht, pp 417–431
Humphrey PPA, Feniuk W, Perren MJ (1990) Anti-migraine drugs in development: advances in serotonin receptor pharmacology. Headache 30:12–16
Humphrey PPA, Feniuk W, Perren MJ (1990) 5-HT in migraine: evidence from 5-HT1-like receptor agonists for a vascular aetiology. In: Sandler M, Collins G (eds) Migraine — a spectrum of ideas. Oxford University Press, Oxford, pp 147–172
Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET (1990) Serotonin and migraine. Ann NY Acad Sci 600:587–598
Ireland SJ, Tyers MB (1987) Pharmacological characterisation of 5-hydroxytryptamine-induced depolarisation of the rat isolated vagus nerve. Br J Pharmacol 90:229–238
Keele CA, Armstrong D (1964) Substances producing pain and itch. Williams and Wilkins, Baltimore
Kimball RW, Friedman AP, Valeejo E (1960) Effect of serotonin in migraine patients. Neurology 10:107–111
Lance JW (1973) The mechanism and management of headache, 2nd edn. Butterworths, London
Lance JW, Anthony M, Hinterberger H (1967) The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 7:93–102
Lataste X, Ferrari MD, Hirt D, Notter M, Wilkinson M (1989) Efficacy and tolerability of ICS 205-930, a 5-HT3 receptor antagonist, in migraine prophylaxis. Cephalalgia 9:346–347
Loisy C, Beorchia S, Centonze V, Fozard JR, Schechter PJ, Tell GP (1985) Effects on migraine headache of MDL 72222 an antagonist at neuronal 5-HT receptors. Double-blind, placebocontrolled study. Cephalalgia 5:79–82
Moskowitz MA (1984) Neurobiology of vascular head pain. Ann Neurol 16:157–168
Moskowitz MA (1987) Sensory connections to cephalic blood vessels and their possible importance to vascular headaches. In: Rose FC (ed) Advances in headache research. John Libbey, London, pp 81–86
Moskowitz MA, Reinhard JF, Romero J, Pettibone DJ (1979) Neurotransmitters and the fifth cranial nerve: is there a relation to headache phase of migraine? Lancet II:883–885
Muck-Seler D, Deanovic Z, Dupelj M (1979) Platelet serotonin (5-HT) and 5-HT releasing factor in plasma of migrainous patients. Headache 19:14–17
Müller-Schweinitzer E, Weidmann H (1978) Basic pharmacological properties. In: Berde B, Schild HO (ed) Ergot alkaloids and related compounds. Handbook of experimental pharmacology. Springer, Berlin, pp 87–232
Mylecharane EJ (1991) 5-HT2 receptor antagonists and migraine therapy. J Neurol 238 (suppl 1):S45-S52
Nichols FT, Mawad M, Mohr JP, Stein B, Hilal S, Michelsen WJ (1990) Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 21:555–559
Olesen J (1985) Migraine and regional cerebral blood flow. Trends in Neurol Sci 8:318–320
Olesen J, Lauritzen M, Tfelt-Hansen P, Henriksen L, Larsen B (1982) Spreading cerebral oligemia in classical and normal cerebral blood flow in common migraine. Headache 22:242–248
Ostfeld AM, Chapman LF, Goodell H, Wolff HG (1957) Studies in headache. Psychosom Med 19:199–208
Ostfeld AM, Wolff HG (1955) Studies on headache: arterenol (norepinephrine) and vascular headache of the migraine type. Arch Neurol Psychiatry 74:131–136
Page IH (1954) Serotonin (5-hydroxytryptamine). Physiol Rev 34:563–588
Peatfield RC (1986) Headache. Springer, Berlin
Peroutka SJ (1990) The pharmacology of current anti-migraine drugs. Headache 30:5–11
Peroutka SJ, McCarthy BG (1989) Sumatriptan (GR43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol 163:133–136
Perrin VL, Färkkilä M, Goasguen J, Doenicke A, Brand J, Tfelt-Hansen P (1989) Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (suppl 9):63–72
Pettibone DJ, Williams M (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33:1531–1535
Raskin NH (1981) Pharmacology of migraine. Annu Rev Pharmacol Toxicol 21:463–478
Ray BS, Wolff HG (1940) Experimental studies on headache: Pain-sensitive structures of the head and their significance in headache. Arch Surg 41:813–856
Remick RA, Keller FD, Gibson RE, Carter D (1989) A comparison between fluoxetine and doxepine in depressed patients. Curr Ther Res 46:842–848
Richardson BP, Engel G, Donatsch P, Stadler PA (1985) Identification of 5-hydroxytryptamine M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316:126–131
Ryan RE (1968) Double-blind crossover comparison of BC-105, methysergide and placebo in the prophylaxis of migraine headache. Headache 8:118–126
Salmon S, Bonciani M, Fanciullacci M, Marianelli L, Michelacci S, Sicuteri F (1982) A putative 5-HT central feedback in migraine and cluster headache attacks. In: Critchley M, Friebman AP, Gurini S, Sicuteri F (eds) Advances in neurology, Vol 33, Headache: physiopathological and clinical concepts. Raven Press, New York, pp 265–274
Schumacher GA, Wolff HG (1941) Experimental studies on headache: A. Contrast of histamine headache with the headache of migraine and that associated with hypertension. B. Contrast of vascular mechanisms in preheadache and in headache phenomena of migraine. Arch Neurol Psychiatry 45:199–214
Sicuteri F (1959) Prophylactic and therapeutic properties of l-methyl-lysergic acid butanolamide in migraine. Int Arch Allergy 15:300–307
Sicuteri F, Testi A, Anselmi B (1961) Biochemical investigations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 19:55–58
Sommerville JM, McLaren EH, Campbell LM, Watson JM (1982) Severe headache and disturbed liver function during treatment with zimelidine. Br Med J 285:1009
Syvälahti E, Kangasniemi P, Ross B (1979) Migraine headache and blood serotonin levels after administration of zimelidine, a selective inhibitor of serotonin uptake. Curr Ther Res 25:299–310
Trautmann E (1928) Die Beeinflussung migräneartiger Zustände durch ein sympathikushemmendes Mittel (Gynergen). Munch Med Wochenschr 75:513
Tzanck A (1928) Le traitement des migraines par le tartrate d'ergotamine. Bull Soc Med Paris 52:1057–1061
Verbeuren TJ (1990) The distribution and biochemistry of 5-hydroxytryptamine in the cardiovascular system. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds): Cardiovascular pharmacology of 5-hydroxytryptamine: prospective therapeutic applications. Kluwer, Dordrecht, pp 3–13
White JC, Sweet WH (1955) Pain: its mechanisms and neurosurgical control. CC Thomas, Springfield
Winther K (1985) Ketanserin — a selective serotonin antagonist, in relation to platelet aggregation and migraine attack rate. Cephalalgia 5(suppl 3):402–403
Wolff HS (1963) Headache and other head pain. Oxford University Press, Oxford
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Humphrey, P.P.A. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 238 (Suppl 1), S38–S44 (1991). https://doi.org/10.1007/BF01642905
Issue Date:
DOI: https://doi.org/10.1007/BF01642905